Contrast-enhanced CT useful for classifying histologic subtypes in epithelial ovarian carcinoma: JAMA

Written By :  Dr Nirali Kapoor
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-26 04:15 GMT   |   Update On 2022-12-26 06:17 GMT
Advertisement

Epithelial ovarian carcinoma (EOC) is the leading cause of death among women with gynecologic malignant tumors. Most EOCs are typically detected at advanced stages, usually with peritoneal metastases. Despite the use of new chemotherapy regimens and targeted therapies, the prognosis remains unsatisfactory, with a 5-year survival rate less than 45%.

Histologic subtypes and International Federation of Gynecology and Obstetrics (FIGO) stages are crucial characteristics for treatment stratification as well as disease prognostication. Epithelial ovarian carcinoma can be classified as high-grade serous carcinoma (HGSC) and non-HGSC according to the different pathways of carcinogenesis.

Advertisement

High-grade serous carcinoma is the most frequent and lethal subtype, accounting for 70% of EOC. Non-HGSC consists of low-grade serous carcinoma, mucinous carcinoma, endometrioid carcinoma, clear cell carcinoma, and malignant Brenner tumors. Non-HGSC presents as an indolent behavior and progresses through a stepwise mutation process, whereas HGSC tends to be more aggressive with greater genetic instability and thereby metastasizes rapidly. With better understanding of the molecular events that support ovarian carcinogenesis, newer tailored therapies and subtype-specific research could be investigated.

Accurate identification of histologic subtypes is vital and will be beneficial for personalized management. In clinical practice, histologic diagnosis is made through surgery or tissue biopsy. Intraoperative frozen section could assist in histologic classification but could still result in misdiagnosis, not to mention the invasive nature of these procedures and associated increase in intraoperative time.

Epithelial ovarian carcinoma has intratumor heterogeneity, especially in large ovarian masses. Radiomics analysis is emerging as a noninvasive and useful tool to assess highly heterogenous malignant tumors, such as HGSCs. Radiomics is a mathematical quantitative analysis that converts medical images into minable, high-dimensional data by extracting large amounts of mathematical features. Previous studies reported the ability of computed tomography (CT)–based radiomics in the evaluation of EOC, including differentiating between EOC and non-EOC, as well as predicting clinical outcome or survival.

To validate these findings based on a large cohort across multiple centers in East Asia, with different machines and varied imaging parameters, the aim of this multicenter study by Mandi Wang and team was to assess the value of CT-based radiomic features in histologic subtyping of EOC.

In this diagnostic study, 665 patients with histologically confirmed epithelial ovarian carcinoma were retrospectively recruited from 4 centers (Hong Kong, Guangdong Province of China, and Seoul, South Korea) between January 1, 2012, and February 28, 2022. The patients were randomly divided into a training cohort (n = 532) and a testing cohort (n = 133) with a ratio of 8:2. This process was repeated 100 times. Tumor segmentation was manually delineated on each section of contrast-enhanced CT images to encompass the entire tumor. Selected features were used to build the logistic regression model for differentiating high-grade serous carcinoma and non–high-grade serous carcinoma.

In this study, 665 female patients (mean [SD] age, 53.6 [10.9] years) with epithelial ovarian carcinoma were enrolled and analyzed. The Dice similarity coefficients of intraobserver and interobserver were all greater than 0.80. Twenty radiomic features were selected for modeling. The areas under the curve of the logistic regression model in differentiating high-grade serous carcinoma and non–high-grade serous carcinoma were 0.837 (95% CI, 0.835-0.838) for the training cohort and 0.836 (95% CI, 0.833-0.840) for the testing cohort.

This multicenter diagnostic study investigated the clinical utility of radiomic features extracted from ceCT based on an LR model in differentiating histologic subtypes of EOC. The proposed CT radiomics model exhibited excellent performance in both the training and testing cohorts, with AUCs of 0.837 and 0.836, respectively. Histologic subtypes of EOC were classified as HGSC and non-HGSC in our study, according to the different pathways of ovarian tumorigenesis. High-grade serous carcinoma tends to have a poorer prognosis compared with non-HGSC, with an increased risk of death. Histologic subtyping also helps in treatment stratification and subtype-specific research in EOC. Therefore, the preoperative prediction of the histologic subtypes in EOC could notably benefit the clinical management and prognosis evaluation.

This multicenter diagnostic study assessed the utility of CT radiomics in discriminating histologic subtypes of EOC. The proposed LR model of CT radiomic features selected by the voted LASSO method demonstrated excellent diagnostic performance in differentiating HGSC and non-HGSC.

Source: Mandi Wang, PhD; Jose A. U. Perucho, PhD; Yangling Hu; JAMA Network Open. 2022;5(12):e2245141. doi:10.1001/jamanetworkopen.2022.45141 (Re

Tags:    
Article Source : JAMA Network Open

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News